Published in Clin Infect Dis on August 01, 2013
Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol (2014) 0.82
Diagnostic accuracy of intracellular uptake rates calculated using dynamic Gd-EOB-DTPA-enhanced MRI for hepatic fibrosis stage. J Magn Reson Imaging (2016) 0.75
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology (2006) 2.62
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology (2012) 1.97
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. J Hepatol (2011) 1.55
HIV drug resistance (HIVDR) in antiretroviral therapy-naïve patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high. PLoS One (2011) 1.45
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J Antimicrob Chemother (2011) 1.26
Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther (2007) 1.09
Epidemiology of Candida blood stream infections in patients with hematological malignancies or solid tumors. Med Mycol (2011) 1.07
Relevance of timing for determination of posaconazole plasma concentrations. Antimicrob Agents Chemother (2011) 1.05
The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection. Ther Drug Monit (2011) 1.02
Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol (2012) 0.99
Uridine pharmacokinetics of mitocnol, a sugar cane extract. AIDS (2005) 0.94
Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. Gastroenterology (2011) 0.94
Linguatuliasis in Germany. Emerg Infect Dis (2006) 0.92
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology (2009) 0.92
The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection. J Gastroenterol (2011) 0.90
Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort). Int J STD AIDS (2005) 0.90
Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography. Antimicrob Agents Chemother (2009) 0.90
Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania. PLoS One (2013) 0.82
Beneficial effects of oral uridine in mitochondrial toxicity. AIDS (2004) 0.82
High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. Cancer Chemother Pharmacol (2010) 0.82
Electrocardiographic spatial QRS-T angle and incident cardiovascular disease in HIV-infected patients (from the Strategies for the Management of Antiretroviral Therapy [SMART] study). Am J Cardiol (2012) 0.81
Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection. J Hepatol (2008) 0.80
No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients. Ann Clin Microbiol Antimicrob (2005) 0.79
Highly sensitive gas chromatographic determination of ethanol in human urine samples. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.78
HIV patients treated with low-dose prednisolone exhibit lower immune activation than untreated patients. BMC Infect Dis (2012) 0.78
Biceps skin-fold thickness may detect and predict early lipoatrophy in HIV-infected children. Pediatr Infect Dis J (2013) 0.77
Rapid determination of nevirapine in human plasma by gas chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 0.77
Impact of benzodiazepines on posaconazole serum concentrations. A population-based pharmacokinetic study on drug interaction. Curr Med Res Opin (2012) 0.76
Drug monitoring of pyrimethamine during maintenance therapy of toxoplasmic encephalitis in patients with advanced HIV infection during HAART. Med Sci Monit (2004) 0.76
Osteomyelitis and skin ulcers caused by Mycobacterium szulgai in an AIDS patient. Scand J Infect Dis (2004) 0.76
Crigler-Najjar syndrome type II in a caucasian patient resulting from two mutations in the bilirubin uridine 5'-diphosphate-glucuronosyltransferase (UGT1A1) gene. J Hepatol (2002) 0.76
The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. AIDS (2016) 0.75
Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection. Clin Infect Dis (2011) 0.75
Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy. Ann Hepatol (2013) 0.75
The per-protocol effect of immediate vs. deferred ART initiation in the START randomized trial. AIDS (2016) 0.75
Are lopinavir and efavirenz serum concentrations in HIV-infected children in the therapeutic range in clinical practice? Paediatr Int Child Health (2013) 0.75